Erasca, Inc. · NASDAQ:ERAS
Erasca — ASCO 2024
11 slides from Erasca's conference presentation, May 2024
Slide 1: Updated results from the Phase 1b/2 HERKULES-3 study: ERAS-007 plus encorafenib and cetuximab
Updated results from the Phase 1b/2 HERKULES-3 study: ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) Aparna Raj Parikh1, E. Gabriela Chiorean2, Chloe E. Atreya3, Lei Zheng4, Scott Kopetz5, Alexander I. Spira6, David R. Spige
Slide 2: Background
2 Background Cetuximab (EGFR inhibitor) EGFR Other RTKS ▪ RAS/MAPK pathway (including BRAF) dysregulation GEF RAS-GDP results in downstream activation of ERK1/2 GRB2 GDP P1 GAP SOS1 GTP ▪ BRAF V600E CRC has worse survival than non-BRAF SHP2 NF1 V600E–mutated CRC, and novel therapies are needed RAS-G
Slide 3: Study Design (NCT05039177)
3 Study Design (NCT05039177) Dose Escalation Dose Expansion Part A2a: EC-naïve or –treated BRAF V600E mCRC Part A2b: EC-naïve BRAF V600E mCRC ERAS-007 125 mg BID-QW + EC ERAS-007 100 mg BID-QW + EC ERAS-007 100 mg BID-QW + EC Part A2c: EC-treated BRAF V600E mCRC ERAS-007 75 mg BID-QW + EC ERAS-007 1
Slide 4: Demographics, Baseline Tumor Characteristics, and Disposition
4 Demographics, Baseline Tumor Characteristics, and Disposition EC Naïve All ERAS-007 100 mg BID-QW + EC pts ERAS-007 100 mg BID- EC Naïve All (N = 20) (N = 29) QW + EC pts (N = 20) (N = 29) Microsatellite instability status (n %) Median age (range) 64.0 (39, 79) 63.0 (39, 86) High 3 (15.0) 6 (20.7)
Slide 5: Safety and Tolerability – TEAEs in ≥10% Pts and Incidence of TRAEs for ERAS-007
Safety and Tolerability – TEAEs in ≥10% Pts and 5 Incidence of TRAEs for ERAS-007* • One DLT of Grade 3 macular edema was reported during dose escalation • TRAEs for ERAS-007 were reported in 89.7% of patients; most events were Grade 1-2 severity (72.4%) • No patients discontinued ERAS-007 or encora
Slide 6: Objective Response Rate
6 Objective Response Rate ERAS-007 100 mg BID-QW + EC pts EC Naïve (N = 20) All (N = 27) Objective response per RECIST (n %) Complete Response (CR) 0 0 Partial Response (PR) 3 (15.0) 3 (11.1) Stable Disease (SD) 12 (60.0) 16 (59.3) Progressive Disease (PD) 4(20.0) 7 (25.9) Not Evaluable (NE) 1 (5.0)
Slide 7: Best % Change in Target Lesions in All and EC Naïve Pts
Best % Change in Target Lesions in All and EC 7 Naïve Pts Diameters from Baseline (%) Measurable Target Lesion Best Change in Sum of * Efficacy-Evaluable Pts * Patient had best overall response of SD prior to the % change in target lesions reaching > -30% at which point the patient had PD; Efficacy-
Slide 8: Duration of Treatment in All and EC Naïve Pts
8 Duration of Treatment in All and EC Naïve Pts Efficacy-Evaluable Pts Median duration of treatment exposure (weeks): All pts - 12.9 (4.0 to 95.9) EC Naïve - 13.0 (4.0 to 95.9) Time on Treatment (weeks) Efficacy-evaluable population includes safety-evaluable pts with a measurable disease at baseline
Slide 9: Key Results and Conclusions
9 Key Results and Conclusions • ERAS-007 (100 mg BID-QW) combined with EC has demonstrated an acceptable safety profile and tolerability in clinical trials, with the majority of ERAS-007-related adverse events being low-grade. • The objective response rate for the ERAS-007 + EC triplet in EC-naïve p
Slide 10: Acknowledgments
10 Acknowledgments The authors would like to thank: • The patients, their families, and caregivers • Participating clinical sites, teams, and investigators, including: o E. Gabriela Chiorean - University of Washington, Fred Hutchinson Cancer Center, Seattle, WA o Chloe E. Atreya - University of Cali
Slide 11: THANK YOU
11 THANK YOU PRESENTED BY: Aparna Raj Parikh, HERKULES-3 study